Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — Caladrius Biosciences — Merger or Acquisition (April 2022)
24 slides from Lisata Therapeutics's merger presentation, Apr 27, 2022
Slide 1: Caladrius and Cend Therapeutics Definitive Merger Agreement
Caladrius and Cend Therapeutics Definitive Merger Agreement Apri l 27, 2022 Proposed combination to create L isata Therapeut ics , a new diversif ied therapeutics company with a robust development pipel ine Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Creating a new diversified therapeutics company, well-positioned for growth
3 Creating a new diversified therapeutics company, well-positioned for growth Lisata Therapeutics (Nasdaq: LSTA) Caladrius is focused on the discovery, development and commercialization of therapies designed to reverse disease and promote the regeneration of damaged tissue. Cend Therapeutics is focu
Slide 4: Lisata Therapeutics overview
Lisata Therapeutics overview Experienced Executive and Development Leadership with extensive domain-relevant expertise David J. Mazzo, Ph.D. – Chief Executive Officer David Slack, M.B.A. – President and Chief Business Officer Kristen K. Buck, M.D. – Executive Vice President of R&D and Chief
Slide 5: Lisata Therapeutics strategic rationale: proprietary platform technology
Lisata Therapeutics strategic rationale 5 The CendR Platform™ provides a targeted tissue penetration capability designed to specifically enhance drug delivery to solid tumors Converts tumor stroma from barrier to a conduit for effective delivery via co-administration of a range of chemo- and immun
Slide 6: Lisata Therapeutics strategic rationale: robust clinical stage pipeline
Lisata Therapeutics strategic rationale 6 Focused on advancing lead product candidate, CEND-1, in a variety of difficult-to-treat solid tumor applications CEND-1 currently in Phase 2b studies in first-line, metastatic pancreatic ductal adenocarcinoma (PDAC) in combination with standard-of-care che
Slide 7: Lisata Therapeutics strategic rationale: compelling value proposition
Lisata Therapeutics strategic rationale Existing Cend strategic partnership in China with Qilu Pharmaceutical with non-dilutive milestone payments, development collaboration and participation in downstream economics Potential for up to $225 million in milestones and royalties on potential sales
Slide 8: CendR Platform Technology Overview
CendR Platform® Technology Overview
Slide 9: (iRGD) mechanism of action
CEND-1 (iRGD) mechanism of action CEND-1, a cyclic peptide, targets tumors by binding to alpha-v (“αv”) integrins, which are selectively expressed on tumor vascular endothelium and not expressed on normal healthy vasculature αv integrins are also expressed on: Cancer-associated fibroblasts, a
Slide 10: (iRGD) mechanism of action: part 1
CEND-1 (iRGD) mechanism of action: part 1 10 αv β3/β5 Tumor Endothelial Cell Co- Admin Drug or Cargo Integrin CEND-1 Protease Peptide Cleaved CEND-1 targets tumor alpha-v integrins, which are selectively expressed on tumor vascular endothelium and not expressed on normal healthy vasculature and tu
Slide 11: (iRGD) mechanism of action: part 2
CEND-1 (iRGD) mechanism of action: part 2 Neuropilin receptor Tumor Endothelial Cell CendR Peptide Fragment Co-administered Anti-cancer therapy CendR Pathway CendR Peptide binds second receptor, Neuropilin to activate CendR Pathway CendR Pathway enables bound and/or co-administered drugs to pene
Slide 12: Preclinical Summary
CEND-1 Preclinical Summary
Slide 13: CEND-1 demonstrates high preclinical specificity for tumor penetration
Mouse model imaging of pancreatic ductal adenocarcinoma (PDAC) with Fluorescent Quantum Dots CEND-1 demonstrates high preclinical specificity for tumor penetration +etch +etch +CEND-1 Braun et al., Nature Mater. 2014; Liu, Braun et al., Nature Comm. 2017 13 Fluorescent Quantum Dots Only Quantum
Slide 14: Increases preclinical tumor penetration and antitumor activity: lung and liver cancer
CEND-1 increases preclinical tumor penetration and antitumor activity Lung cancer + gemcitabine Liver cancer + kinase inhibitor (sorafenib) 14 In nude mice transplanted with human lung cancer cell line A549, the addition of CEND-1 to gemcitabine synergistically reduced tumor volume vs either agent
Slide 15: Increases preclinical tumor penetration and antitumor activity: breast cancer
CEND-1 increases preclinical tumor penetration and antitumor activity Breast cancer + antibody (Herceptin®) Breast cancer + nanoparticle (Abraxane) 15 In nude mice transplanted with human breast cancer cell line BT474, the addition of CEND-1 to trastuzumab synergistically reduced tumor volume vs e
Slide 16: Increases preclinical tumor penetration and antitumor activity: gastric cancer
CEND-1 increases preclinical tumor penetration and antitumor activity 16 Gastric cancer + adoptive cell therapy In mouse model with gastric cancer cell line SNU719, CEND-1 significantly enhanced antitumor activity of adoptive cell immunotherapy
Slide 17: Prolongs preclinical survival in PDAC tumor models
CEND-1 prolongs preclinical survival in PDAC tumor models Pancreatic ductal adenocarcinoma Liu et al, JCI, 2017 In the tumor-bearing B6/129 mouse model of PDAC, the addition of CEND-1 to irinotecan nanoparticles enhanced survival vs either treatment alone Pancreatic ductal adenocarcinoma Hurtado d
Slide 18: Clinical Summary
hg , a j oe \\ . CEND-1 [> Clinical Summary
Slide 19: CEND-1 Phase 1b (AUS) PDAC clinical trial results summary
Indication: first-line metastatic pancreatic ductal adenocarcinoma (PDAC) Treatment: CEND-1 / Gemcitabine / Nab-Paclitaxel Size: 31 subjects enrolled; 29 evaluable first-line Sites: 3 in Australia from August 2018 - June 2020 CEND-1 well-tolerated, no dose-limiting toxicities; safety of combo co
Slide 20: Results suggest superior performance vs. SoC
CEND-1 results suggest superior performance vs. SoC a12 December 2020, including patients under compassionate use protocol b Investigator assessed 20 Gemcitabine + nab- paclitaxel (NEJM 2013) CEND-1 + Gemcitabine + nab- paclitaxel (ESMO 2020) Gemcitabine (NEJM 2011) Folfirinox (NEJM 2011) N 431 29 1
Slide 21: Lisata Therapeutics Combined Pipeline
Lisata Therapeutics Combined Pipeline
Slide 22: Lisata Therapeutics pipeline of novel product candidates
Lisata Therapeutics pipeline of novel product candidates Product Indication Preclinical Phase 1 Phase 2 Phase 3 Cend Pipeline CEND-1 + gemcitabine/nab-paclitaxel First-Line mPDAC (Metastatic Pancreatic Ductal Adenocarcinoma)CEND-1 + SoC chemo + anti-PD(L)1 CEND-1 + FOLFIRINOX PDAC (Resectable & Bord
Slide 23: Lisata Therapeutics anticipated milestones
Lisata Therapeutics anticipated milestones 23 2022 2023 2024 Cend Pipeline Programs Caladrius Pipeline Programs CEND-1 Ph2 in mPDAC (Aus) initiation planned 2Q 2022 CEND-1 Ph1 in mPDAC + PD(L)1 initiation planned 4Q 2022 CEND-1 Ph1b/2 in mPDAC (Qilu; China) preliminary data expected 1H 2023 CEND-1 P
Slide 24: Caladrius and Cend Therapeutics Definitive Merger Agreement
Caladrius and Cend Therapeutics Definitive Merger Agreement Apri l 27, 2022 Proposed combination to create L isata Therapeut ics , a new diversif ied therapeutics company with a robust development pipel ine
Caladrius Biosciences — Merger or Acquisition (April 2022) on 6ix